New cocktail targets rare tumor in kids

NCT ID NCT01189643

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial adds three drugs—irinotecan, temozolomide, and bevacizumab—to the usual chemotherapy for newly diagnosed desmoplastic small round cell tumor (DSRCT), a rare and aggressive cancer. The study includes 15 patients aged 1 to 30 and aims to see if the combination is safe and tolerable. Researchers will also check how well the tumor responds and track survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: irinotecan, temozolomide, and bevacizumab (chemotherapy drugs)
What this could lead to: If it works, this could point toward a more effective treatment for desmoplastic small round cell tumor, a rare and aggressive cancer.
What could go wrong: This is a very early pilot trial with only 15 participants, so results may not apply to all patients. The added drugs may cause more side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

desmoplastic small round cell tumor sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT) SARCOMA

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.